Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.51 |
| ▸ | CA12 | O43570 | 10/20 | 0.45 |
| ▸ | CA1 | P00915 | 10/20 | 0.45 |
| ▸ | CA9 | Q16790 | 10/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5805371 | 0.83 | CA2 (0.61) | CA2CA12CA1CA9 | |
| SCHEMBL5802110 | 0.83 | CA2 (0.59) | CA2CA12CA1CA9 | |
| SCHEMBL5803011 | 0.83 | CA2 (0.48) | CA2CA12CA1CA9 | |
| SCHEMBL5804779 | 0.80 | CA2 (0.47) | CA2CA12CA1CA9 | |
| SCHEMBL11126864 | 0.80 | MAPT (0.41) | CA2NR1H2 | |
| SCHEMBL9828623 | 0.79 | CA2 (0.49) | CA2CA12CA1CA9 | |
| SCHEMBL5804819 | 0.78 | CA2 (0.48) | CA2CA12CA1CA9 | |
| SCHEMBL5808776 | 0.78 | LOX (0.45) | CA2CA12CA1CA9 | |
| SCHEMBL10372120 | 0.76 | CA2 (0.74) | CA2CA12CA1CA9 | |
| SCHEMBL5804507 | 0.72 | CA2 (0.49) | CA2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0126684-B1 | DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS | MERCK & CO. INC. (US) | 1991-08-28 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| WO-2025108987-A1 | COMPOSITIONS AND METHODS FOR TREATING EYETEAR FILM DEFICIENCY AND REDEYE | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-05-30 | — | — | WO | disclosed |
| CN-118813026-A | Water-soluble supramolecular complexes | 博任达生化科技（上海）有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118813027-A | Water-soluble supramolecular complexes | 博任达生化科技（上海）有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-107108905-B | Water-soluble supramolecular complexes | 博任达生化科技（上海）有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2024110505-A1 | METHODS FOR TREATING EYETEAR FILM DEFICIENCY | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024110503-A1 | METHODS FOR TREATING EYETEAR FILM DEFICIENCY | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-05-30 | — | — | WO | disclosed |
| US-20240165147-A1 | Methods for Treating Eyetear Film Deficiency | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-05-23 | — | — | US | disclosed |
| US-20240165019-A1 | Methods for Treating Eyetear Film Deficiency | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-05-23 | — | — | US | disclosed |
| EP-0227494-B1 | PHARMACEUTICAL COMPOSITION OF THE TYPE WHICH UNDERGOES LIQUID-GEL PHASE TRANSITION | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET (FR) | 1992-03-04 | — | — | EP | disclosed |
| WO-1991019481-A1 | REVERSIBLE GELATION COMPOSITIONS AND METHODS OF USE | ALLERGAN, INC. (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0126684-B1 | DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS | MERCK & CO. INC. (US) | 1991-08-28 | — | — | EP | disclosed |
| EP-0437368-A1 | Fluid ophthalmic composition based on lipid microparticles containing at least one active principle | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET (FR) | 1991-07-17 | — | — | EP | disclosed |
| EP-0424042-A1 | Non-solid ophthalmic composition and process for preparing the said composition | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET (FR) | 1991-04-24 | — | — | EP | disclosed |
| US-4861760-A | Ophthalmological composition of the type which undergoes liquid-gel phase transition | MERCK & CO., INC. (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0227494-A1 | Pharmaceutical composition of the type which undergoes liquid-gel phase transition | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET (FR) | 1987-07-01 | — | — | EP | disclosed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | disclosed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | disclosed |